several studies have reviewed the potential coadjuvant of radiotherapy (rt) and chemotherapy in the treatment of ovary cancer. however the effectiveness of total abdomen rt (rtat) versus new qt drugs have not been adequately compared. both surgery and qt prior to rt increase total and freedom from the disease since tumors become radiosensitive, thus favoring destruction. diverse techniques such as imrt (intensity modulated radiation therapy) are being used with excellent results. despite these advances, many of the patients develop intrabdominal recurrence leaving them out of the therapeutic scope/range for qt. rt may then be used as a palliative in big unique cases watching possible complications. rtat may eventually be restarted in the treatment of ovary cancer depending on the findings during surgery. finally, rt/qt concomitants have shown their effect in sensitivity and synergy and it is expected that new drugs with different interactions such as taxan and target molecules are added. treatment of ovarian cancer remains essentially surgical and with chemotherapy, but both radio and chemotherapy has demonstrated their adjuvant effect. despite being an unexplored alternative is necessary to study prospectively the promising results of new techniques of radiation therapy in these patients.